Role of bone-forming agents in the management of osteoporosis

被引：28
|
作者：
McClung, Michael R. [1 ,2 ]
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR 97225 USA
[2] Australian Catholic Univ, Mary MacKillop Ctr Hlth Res, Melbourne, Vic, Australia
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2021年 / 33卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Osteoporosis; Osteoanabolic; Abaloparatide; Romosozumab; Teriparatide; Sequence;
D O I：
10.1007/s40520-020-01708-8
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-remodeling drugs for rapid improvement in bone density and fracture risk reduction, providing strong justification for the use of these anabolic agents as the initial therapy in high-risk patients, to be followed by anti-remodeling therapy. This review will highlight the results of recent studies and define the current status of osteoanabolic therapy for osteoporosis.
引用
收藏
页码：775 / 791
页数：17
相关论文
共 50 条
  • [41] Proceedings of the 2024 Santa Fe Bone Symposium: Update on the Management of Osteoporosis and Rare Bone Diseases
    Lewiecki, E. Michael
    Bilezikian, John P.
    Clark, Amanda
    Collins, Michael T.
    Kado, Deborah M.
    Lane, Joseph
    Langdahl, Bente
    Mcclung, Michael R.
    Snyder, Peter J.
    Stein, Emily M.
    JOURNAL OF CLINICAL DENSITOMETRY, 2025, 28 (01)
  • [42] Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases
    Lewiecki, E. Michael
    Anderson, Paul A.
    Bilezikian, John P.
    Binkley, Neil
    Cheung, Angela M.
    Imel, Erik A.
    Krueger, Diane
    McClung, Michael R.
    Miller, Paul D.
    Rothman, Micol S.
    JOURNAL OF CLINICAL DENSITOMETRY, 2022, 25 (01) : 3 - 19
  • [43] Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis
    Burr D.B.
    Clinical Reviews in Bone and Mineral Metabolism, 2016, 14 (3): : 197 - 217
  • [44] Endocortical bone loss in osteoporosis: the role of bone surface availability
    Buenzli, Pascal R.
    Thomas, C. David L.
    Clement, John G.
    Pivonka, Peter
    INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING, 2013, 29 (12) : 1307 - 1322
  • [45] The importance of bone remodelling parameters in the management of osteoporosis
    Topyurek, Devran
    Meier, Christian
    Kranzlin, Marius E.
    THERAPEUTISCHE UMSCHAU, 2025, 82 (01) : 2 - 9
  • [46] Bone turnover markers in the management of postmenopausal osteoporosis
    Brown, Jacques P.
    Albert, Caroline
    Nassar, Bassam A.
    Adachi, Jonathan D.
    Cole, David
    Davison, K. Shawn
    Dooley, Kent C.
    Don-Wauchope, Andrew
    Douville, Pierre
    Hanley, David A.
    Jamal, Sophie A.
    Josse, Robert
    Kaiser, Stephanie
    Krahn, John
    Krause, Richard
    Kremer, Richard
    Lepage, Raymond
    Letendre, Elaine
    Morin, Suzanne
    Ooi, Daylily S.
    Papaioaonnou, Alexandra
    Ste-Marie, Louis-Georges
    CLINICAL BIOCHEMISTRY, 2009, 42 (10-11) : 929 - 942
  • [47] Paeonolide as a Novel Regulator of Core-Binding Factor Subunit Alpha-1 in Bone-Forming Cells
    Park, Kyung-Ran
    Lee, Joon Yeop
    Cho, Myounglae
    Hong, Jin Tae
    Yun, Hyung-Mun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [48] Use of bone turnover markers in the management of osteoporosis
    Jain, Sumeet
    Camacho, Pauline
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2018, 25 (06) : 366 - 372
  • [49] The use of anabolic agents in the treatment of osteoporosis: a clinical update
    Inderjeeth, Charles A.
    Inderjeeth, Diren C.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2024, 31 (04) : 157 - 163
  • [50] Fast and Slow Bone LosersRelevance to the Management of Osteoporosis
    Stephen Hough
    Drugs & Aging, 1998, 12 : 1 - 7
12345